Pharma major Dr Reddy's Laboratories (DRL) is gearing up for taking its new anti-cholesterol drug to Phase II trials.
Though the company officials did not specify any timeframe for the programme, the completion of Phase I trials has apparently given satisfactory results to take the drug to the next level.
The new drug under development is targeted at reducing the risk of heart attacks. "The cholesterol ester transfer protein (CETP) has completed the first phase of human trials.
We would look at taking it to the next level," DRL chairman Dr. K. Anji Reddy said.
In fact, the CETP shuttles the cholesterol throughout the body thus controlling of lipoprotein in the body. The completion of Phase I implies that the company has already found the drug to be safe though the efficacy and other issues will have to be tested in the subsequent phases.
Scientist’s world over have been holding a mixed opinion about the efficacy of CETP in checking the incidence of heart attack and another drug major Pfizer had earlier stopped the development of the CETP inhibitor drug citing safety concerns.
According Reddy, Merck has made some progress in CETP inhibitor while DRL, too, would move ahead. Roche is the other company that is focusing on developing a drug in this class.
However, Merck's drug is slated to come up for approvals sometime in 2014 while Roche would file the documents in 2012.